At the 65th ASH Annual Meeting, Sylvain Garciaz, MD, shared insights on the potential benefit of stopping venetoclax and/or azacytidine treatment for responding patients with acute myeloid leukemia.
At the 65th ASH Annual Meeting, Sylvain Garciaz, MD, shared insights on the potential benefit of stopping venetoclax and/or azacytidine treatment for responding patients with acute myeloid leukemia.
At the 65th ASH Annual Meeting,...